Transcription of *Continue medication at each stage if EITHER ...
{{id}} {{{paragraph}}}
1st LINEIn ADDITION to lifestyle measuresSET GLYCAEMIC TARGET: HbA1c <7% (53 mmol/mol) OR INDIVIDUALISED AS AGREEDUSUAL APPROACHALTERNATIVE APPROACH: if osmotic symptoms or intolerant of metforminMETFORMIN*EFFICACYMODERATECV BENEFITYESHYPOGLYCAEMIA RISKLOWWEIGHTREDUCTIONMAIN ADVERSE EVENTSGASTROINTESTINALIN CKD stage 3 AMAXIMUM 2 g DAILY2nd LINEIn ADDITION to lifestyle measuresIF NOT REACHING TARGET AFTER 3 6 MONTHS 2, REVIEW ADHERENCE: THEN GUIDED BY PATIENT PROFILEADD ONE OF:SULPHONYLUREA* ORSGLT2 INHIBITOR* ORDPP-4 INHIBITOR* ORPIOGLITAZONE*EFFICACYHIGHMODERATELOW/M ODERATEMODERATECV BENEFITNOYES (SPECIFIC AGENTS) 3 NOPROBABLE (BUT FLUID RETENTION)HYPOGLYCAEMIA RISKHIGHLOWLOWLOWWEIGHTGAINLOSSNEUTRALGA INMAIN ADVERSE EVENTSHYPOGLYCAEMIAGENITAL MYCOTICFEWOEDEMA/FRACTURES 6IN CKD stage 3 ACAREFUL MONITORING 1DO NOT INITIATE 4 REDUCE DOSE 5 DOSE UNCHANGED3rd LINEIn ADDITIO
1st LINE In ADDITION to lifestyle measures SET GLYCAEMIC TARGET: HbA1c <7% (53 mmol/mol) OR INDIVIDUALISED AS AGREED USUAL APPROACH ALTERNATIVE APPROACH: if osmotic symptoms or intolerant of metformin
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}